WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H125681
CAS#: 257943-19-4
Description: Hynic-TOC is a ligand for making 99mTc-Hynic-TOC as an imaging agent in the diagnostic of neuroendocrine tumor.
Hodoodo Cat#: H125681
Name: Hynic-TOC
CAS#: 257943-19-4
Chemical Formula: C55H71N13O12S2
Exact Mass: 1,169.48
Molecular Weight: 1,170.370
Elemental Analysis: C, 56.44; H, 6.11; N, 15.56; O, 16.40; S, 5.48
Synonym: HYNIC-Tyr3-octreotide; Hynic-TOC; HynicTOC; Hynic TOC; Hydrazinonicotinyl-Tyr3-octreotide
IUPAC/Chemical Name: (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazineylidene-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
InChi Key: WJBPMDZACHSXSD-HLAGHTPDSA-N
InChi Code: InChI=1S/C55H71N13O12S2/c1-30(70)43(27-69)64-54(79)45-29-82-81-28-44(65-51(76)40(22-32-10-4-3-5-11-32)61-48(73)34-17-20-46(68-57)59-25-34)53(78)62-41(23-33-15-18-36(72)19-16-33)50(75)63-42(24-35-26-58-38-13-7-6-12-37(35)38)52(77)60-39(14-8-9-21-56)49(74)67-47(31(2)71)55(80)66-45/h3-7,10-13,15-20,25-26,30-31,39-45,47,58,69-72H,8-9,14,21-24,27-29,56-57H2,1-2H3,(H,59,68)(H,60,77)(H,61,73)(H,62,78)(H,63,75)(H,64,79)(H,65,76)(H,66,80)(H,67,74)/t30-,31-,39+,40-,41+,42-,43-,44+,45+,47+/m1/s1
SMILES Code: O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](NC(C(C=C/2)=CNC2=N\N)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 1,170.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi
L. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors
of the Lung (and in other Malignant and Benign Pulmonary Diseases). Curr
Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610. PMID:
31886756; PMCID: PMC8193811.
2: Garai I, Barna S, Nagy G, Forgacs A. Limitations and pitfalls of 99mTc-
EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med Rev Cent East Eur.
2016;19(2):93-8. doi: 10.5603/NMR.2016.0019. PMID: 27479887.
3: Shi X, Jing H, Li F, Zhao Y, Wang Z, Huo L. 99mTc-HYNIC-TOC in the Evaluation
of Recurrent Tumor-Induced Osteomalacia. Clin Nucl Med. 2019 Mar;44(3):209-213.
doi: 10.1097/RLU.0000000000002458. PMID: 30672760.
4: Li B, Duan L, Li X, Shi J, Li H, Liu H, Cheng X, Wu X, Gao Y. Diagnostic
accuracy of 99mTc-HYNIC-TOC SPECT/CT for detecting osteomalacia-
associated tumors. Front Oncol. 2023 Jul 24;13:1228575. doi:
10.3389/fonc.2023.1228575. PMID: 37554164; PMCID: PMC10405922.
5: Liepe K, Becker A. 99mTc-Hynic-TOC imaging in the diagnostic of
neuroendocrine tumors. World J Nucl Med. 2018 Jul-Sep;17(3):151-156. doi:
10.4103/wjnm.WJNM_41_17. PMID: 30034278; PMCID: PMC6034543.
6: Chaib S, Hallouard F, Chennell P, Darcissac C, Morelec I, Rioufol C, Sautou
V, Fraysse M. Compatibility of [99mTc]Tc-EDDA/HYNIC-TOC and [68Ga] Ga-DOTA-TOC
in a syringe for intravenous administration. Nucl Med Commun. 2020
Jan;41(1):11-17. doi: 10.1097/MNM.0000000000001108. PMID: 31764593.
7: Hou G, Jiang Y, Li F, Zhu Z, Jing H. Site-based performance of 131I-MIBG
imaging and 99mTc-HYNIC-TOC scintigraphy in the detection of nonmetastatic
extra-adrenal paraganglioma. Nucl Med Commun. 2022 Jan 1;43(1):32-41. doi:
10.1097/MNM.0000000000001490. PMID: 34570039; PMCID: PMC8654250.
8: Gherghe M, Lazăr AM, Stanciu AE, Mutuleanu MD, Sterea MC, Petroiu C, Galeș
LN. The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a
Feasible Choice for Diagnosing Gastroenteropancreatic NETs? Cancers (Basel).
2022 May 31;14(11):2725. doi: 10.3390/cancers14112725. PMID: 35681704; PMCID:
PMC9179571.
9: Sager S, Kabasakal L, Halac M, Maecke H, Uslu L, Önsel Ç, Kanmaz B.
Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG
PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Clin Nucl Med. 2013 May;38(5):321-5. doi: 10.1097/RLU.0b013e3182868062. PMID:
23531772.
10: Boutsikou E, Porpodis K, Chatzipavlidou V, Hardavella G, Gerasimou G, Domvri
K, Papadopoulos N, Avramidou V, Spyratos D, Kontakiotis T, Zarogoulidis K.
Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor
Diagnosis. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819842586. doi:
10.1177/1533033819842586. PMID: 31079574; PMCID: PMC6535698.
